“Cheaper and better”: Societal cost savings and budget impact of changing from systemic to intralesional pentavalent antimonials as the first-line treatment for cutaneous leishmaniasis in Bolivia

Simple item page
dc.contributor.authorDaniel Eid Rodríguez
dc.contributor.authorMiguel San Sebastiån
dc.contributor.authorAnni‐Maria Pulkki‐Brännström
dc.coverage.spatialBolivia
dc.date.accessioned2026-03-22T14:18:56Z
dc.date.available2026-03-22T14:18:56Z
dc.date.issued2019
dc.descriptionCitaciones: 15
dc.description.abstractThe results of this study support a shift to ILPA as the first-line treatment for CL in Bolivia and possibly in other South American countries.
dc.identifier.doi10.1371/journal.pntd.0007788
dc.identifier.urihttps://doi.org/10.1371/journal.pntd.0007788
dc.identifier.urihttps://andeanlibrary.org/handle/123456789/45795
dc.language.isoen
dc.publisherPublic Library of Science
dc.relation.ispartofPLoS neglected tropical diseases
dc.sourceUniversity of San Simón
dc.subjectMedicine
dc.subjectEconomic shortage
dc.subjectChristian ministry
dc.subjectCutaneous leishmaniasis
dc.subjectNeglected tropical diseases
dc.subjectBusiness
dc.subjectEnvironmental health
dc.subjectLeishmaniasis
dc.title“Cheaper and better”: Societal cost savings and budget impact of changing from systemic to intralesional pentavalent antimonials as the first-line treatment for cutaneous leishmaniasis in Bolivia
dc.typearticle

Files

Collections

Artículo Científico Publicado